-+ 0.00%
-+ 0.00%
-+ 0.00%

CalciMedica Q1 FY26 results swing to net income of $5 million

PUBT·05/12/2026 11:03:34
Listen to the news
CalciMedica Q1 FY26 results swing to net income of $5 million
  • CalciMedica swung to net income of USD 5 million, or USD 0.31 per basic share, for first-quarter 2026 results, versus a net loss of USD 5 million a year earlier.
  • Other income more than doubled to USD 10.6 million, driven by fair value adjustments to promissory note and common stock warrants.
  • R&D expense fell 16.67% to USD 3.5 million, on lower preclinical and clinical trial activity and reduced chemistry, manufacturing and controls work.
  • Cash and cash equivalents totaled USD 8.2 million, with funding expected to last into fourth-quarter 2026.
  • FDA feedback on Auxora pivotal program design in acute pancreatitis and potential future development in acute kidney injury is expected in second-quarter 2026; an IND submission for oral CRAC channel inhibitor CM5480 in pulmonary hypertension is anticipated in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CalciMedica Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-218134), on May 12, 2026, and is solely responsible for the information contained therein.